Results 291 to 300 of about 276,897 (341)

Tumor immune microenvironment and immune phenotypes in PD-L1-tested canine urothelial carcinoma. [PDF]

BMC Vet Res
Muscatello LV, D'Annunzio G, Franceschini T, Tugnoli C, Grillini A, Bacci B, Avallone G, Valenti P, Giuliano A, Fiorentino M, Volpatti D, Sarli G.   +11 more
europepmc   +1 more source

Core Fucosylation Represses SMURF1‐Dependent Degradation of CD47 to Promote Tumor Immune Evasion

Advanced Science, EarlyView.
FUT8‐mediated core fucosylation of CD47 at N111 blocks SMURF1 binding and reduces CD47 ubiquitination and degradation. Blocking N111 glycosylation reduces CD47 expression and promotes macrophage phagocytosis of tumor cells. Furthermore, ablating CD47 core fucosylation boosts CD103+ dendritic cells (DCs) infiltration, increases natural killer (NK) cell ...
Yuting Cao, Siyuan Chai, Mingyang Li, Xiaoming Chen, Jiating Hu, Bingyi Lin, Liming Wu, Wen Yi, Qiang Zhu   +8 more
wiley   +1 more source

Evaluation of warning strategies for paraneoplastic neurological syndromes associated with PD-1/PD-L1 inhibitors. [PDF]

Front Immunol
Ren Z, Liu Y, Liu J, Qi X, Qiu F, Sun C.
europepmc   +1 more source

Spatially Resolved Multiomics Reveals Metabolic Remodeling and Autophagy Activation in Adamantinomatous Craniopharyngiomas

Advanced Science, EarlyView.
Multiomics integration analysis reveals the “cystic fluid–tumor cell” metabolic coupling that mediates active choline/ethanolamine uptake of tumor cells from cystic fluid and PC/PE synthesis pathways reprogramming that mediating autophagy pathway activation within ACP. ABSTRACT Adamantinomatous craniopharyngioma (ACP), a benign yet highly recurrent and
Dongting Chen, Yahui Gao, Yulin Wang, Ting Lei, Zheng Qu, Yuhan An, Jiaxu Fu, Xin Li, Fangjun Liu, Yan Li   +9 more
wiley   +1 more source

PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment. [PDF]

J Immunother Cancer
King LA, Veth M, Roos M, Scheffer GL, Popovic MA, de Gruijl TD, van der Vliet HJ.   +6 more
europepmc   +1 more source

OCTN2 Activates a Non‐Canonical Carnitine Metabolic Pathway to Promote MASH‐HCC Progression and Immunotherapy Resistance

Advanced Science, EarlyView.
In non‐MASH‐HCC, L‐carnitine promotes tumor progression primarily through its classical role in enhancing fatty acid oxidation (FAO). However, in MASH‐HCC, where FAO is markedly suppressed, L‐carnitine shifts from this canonical function to serve instead as an intracellular acetyl group buffer.
Chuqi Xia, Xiao Zhang, Jinze Li, Ning Xu, Sheng Hu, Qiyu Lu, Yuxuan Li, Taifu Xiao, Xu Li, Xue Wang, Kequan Xu, Daoming Liang   +11 more
wiley   +1 more source

Prognostic value of manual and digital PD-L1 expression in pT3 and pT4 colon cancer. [PDF]

Diagn Pathol
Jepsen DNM, Jensen MB, Bennedsen ALB, Grantzau TL, Eriksen TT, Eriksen JO, Bzorek M, Gögenur I, Fiehn AK.   +8 more
europepmc   +1 more source

Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells

Advanced Science, EarlyView.
ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen, Di Lu, Rukang Liang, Weikeng Tan, Erming Zhao, Sihuang Wu, Xintong Li, Yulong Song, Miaojian Wan, Xiaoyuan Xie, Qi Zhang, Qiuli Liu   +11 more
wiley   +1 more source

mTORC2 inhibition reduces tumor burden via STAT1 activation and enhanced response to anti-PD-L1 therapy. [PDF]

Cell Death Dis
Gschwendtner A, Schütz B, Mirea MA, Eckel O, Kepa MZ, Fritsch SD, Oberle R, Weichhart T, Hengstschläger M, Mikula M.   +9 more
europepmc   +1 more source

TOPK Inhibition Promotes Anti‐Tumor Immunity Via eIF4F Complex Mediated STAT1 Translation in Gastric Cancer

Advanced Science, EarlyView.
This study identifies TOPK as a dual‐function target in gastric cancer: it drives tumor cell proliferation and migration, and under IFN‐γ stimulation, phosphorylates eIF4F complex component eIF4A1 to enhance STAT1 mRNA translation, thereby promoting PD‐L1/IDO1‐mediated tumor immunometabolic evasion.
Junbing Chen, Longtao Huangfu, Gangjian Wang, Xueying Wang, Huanbo Zhu, Qian Yao, Cong Chen, Xiaohuan Tang, Ting Guo, Biao Fan, Xingyang Liu, Qingda Li, Zining Liu, Ying Hu, Tianze Sun, Jiafu Ji, Xiaofang Xing   +16 more
wiley   +1 more source